The real world experience of Australian patients with non-melanoma solid tumours receiving anti-PD-1 checkpoint inhibitors appears to reflect clinical trial data. The findings provide some additional evidence to support patient decision-making around self-funding costly treatments such as pembrolizumab (Keytruda) or nivolumab (Opdivo). A review of 47 patients at the Peter MacCallum Cancer Centre found those ...
Real world data on non-PBS funded checkpoint inhibitors
By Mardi Chapman
7 Mar 2018